Acadia Pharmaceuticals: Leerink Partners cuts target price to $27 from $30
ACAD•Leerink Partners cut its target price for Acadia Pharmaceuticals to $27 from $30.
Related News
Goldman executives reportedly set for more than $500 million in special bonuses
GS•
Snap-on schedules third-quarter results conference call webcast
SNA•
First Majestic Silver Q3 production falls 11% to 3.4 million oz after San Dimas labor dispute
AG•
Chime Financial raised to buy from hold at Deutsche Bank; price target raised to $35 from $30
CHYM•
Clearmind says Japan publishes patent application on 3-MMC-based dyskinesia treatment
CMND•